Rare but serious side effects include pancreatitis, gallbladder problems, and kidney changes
therefore, researchers warn that it carries the identical theoretical risk of exacerbating oncological conditions by promoting new blood vessel formation within tumor microenvironments, rendering it unsafe for use in patients with a history of cancer
Additionally, age related changes are likely to be region-dependent
Abbott AE Jr, Hill RC, Flynn MA, McClure S, Murray GF
Until those data mature, clinicians should frame Wegovys MASH indication as evidencesupported for histologic response but still under confirmatory evaluation for hard liver outcomes. Safety profile and risk management Safety considerations for Wegovy are dominated by its GLP1 class effects and includes both common, generally manageable GI symptoms and less frequent but clinically significant risks
Holst, who discovered and described GLP-1, explains its role as a gut-derived hormone that regulates appetite, insulin secretion, and digestion, offering a groundbreaking approach to managing obesity and type 2 diabetes
